acadesine

Trade name: arasine

Small moleculeexperimental

Clinical trial activity

4 trials · 9 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Oct 1, 2002 (NCT00168519)

Timeline

2000s

Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Jan 1, 2009
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

AMP-activated protein kinase, AMPKACTIVATOR
AMP-activated protein kinase, AMPK activator
AMP-activated protein kinase, AMPKAGONIST
AMP-activated protein kinase, AMPK agonist

Chemistry & pharmacology

Loading structure…

SMILES

NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N

Mol. weight: 258.23 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

ChEMBLCHEMBL1551724 ↗

Also known as

1-(5'-phosphoribosyl)-5-amino-4-imidazolecarboxamide
1-(5'-phosphoribosyl)-5-amino-4-imidazolecarboxamide
1-ribosyl-4-carboxamido-5-aminoimidazole
4-carboxy-5-aminoimidazole ribotide
5-amino-1-(5-phospho-d-ribosyl)imidazole-4-carboxamide
5-amino-1-(5-phospho-d-ribosyl)imidazole-4-carboxamide
5-amino-1-beta-d-ribofuranosyl-4-imidazolecarboxamide
5-amino-1-beta-d-ribofuranosylimidazole-4-carboxamide monophosphate
5-amino-4-imidazolecarboxamide ribofuranoside 5'-monophosphate
5-aminoimidazole-4-carboxamide 1-ribofuranoside
5-aminoimidazole-4-carboxamide riboside
5-aminoimidazole-4-carboxamide riboside
5-aminoimidazole-4-carboxamide ribotide
5-aminoimidazole-4-carboxamide ribotide
5-phosphoribosyl-4-carbamoyl-5-aminoimidazole
5-phosphoribosyl-4-carbamoyl-5-aminoimidazole
5'-phospho-ribosyl-5-amino-4-imidazole carboxamide
5'-phospho-ribosyl-5-amino-4-imidazole carboxamide
5'-phosphoribosyl-5-amino-4-imidazolecarboxamide
5'-phosphoribosyl-5-amino-4-imidazolecarboxamide
5'-phosphoribosyl-5-amino-4-imidazolecarboxamide
acadesine
acadesine
acadesine
acadesine
acadesine
acadesine
acadesine
acadesine 5'-monophosphate
acadesine 5'-monophosphate
aicar
aicar
aicar
aicar
aica ribofuranoside
aica ribonucleoside
aica ribonucleotide
aica ribonucleotide
aica ribonucleotide
aica-ribonucleotide
aica-ribonucleotide
aica ribonucleotide, (d-ribofuranosyl)-isomer
aica riboside
aica-riboside
aica-riboside
aicariboside 5'-monophosphate
aminoimidazole carboxamide ribonucleoside
aminoimidazole carboxamide ribonucleoside
aminoimidazole carboxamide ribonucleoside
aminoimidazole carboxamide ribonucleoside
aminoimidazole carboxamide ribonucleoside
aminoimidazole carboxamide ribonucleoside
aminoimidazole carboxamide ribonucleotide
ara100
ara 100
ara-100
arasine
arasine
cair
gp 1 110
gp-1-110
gp-1-110
zmp
z-nucleotide
z-riboside

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01813838	Phase 1/Phase 2 (Phase 2)	Jun 1, 2013	Advancell - Advanced In Vitro Cell Technologies, S.A., Groupe Francophone des Myelodysplasies
NCT00872001	Phase 3	Apr 1, 2009	Duke University, Merck
NCT00559624	Phase 1/Phase 2 (Phase 2)	Dec 1, 2007	Advancell - Advanced In Vitro Cell Technologies, S.A., Nexus Oncology Ltd, Université catholique de Louvain
NCT00168519	N/A	Oct 1, 2002	Monash University, National Health and Medical Research Council, Australia, Roche

Showing 4 of 4 trials

Page 1 / 1

Organizations

Research & Development (9)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Advancell - Advanced In Vitro Cell Technologies, S.A.	For profit	2	1	1	2007
Duke University	Academic/Hospital	1	0	1	2009
Groupe Francophone des Myelodysplasies	Academic/Hospital	1	1	1	2013
Merck	For profit	1	1	1	2009
Monash University	Academic/Hospital	1	1	1	2002
National Health and Medical Research Council, Australia	Government	1	0	1	2002
Nexus Oncology Ltd	For profit	1	0	1	2007
Roche	For profit	1	0	1	2002
Université catholique de Louvain	Academic/Hospital	1	0	1	2007

9 organizations

Page 1 / 1